Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.

2.

Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer.

Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, Wilmink JW, Groot Koerkamp B, van Laarhoven HW, Besselink MG.

Br J Surg. 2019 Feb 13. doi: 10.1002/bjs.11111. [Epub ahead of print] Review.

PMID:
30758855
3.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

4.

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.

Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, van Laarhoven HWM.

J Cachexia Sarcopenia Muscle. 2019 Jan 21. doi: 10.1002/jcsm.12371. [Epub ahead of print]

5.

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy.

Kok DE, van den Berg MMGA, Posthuma L, van 't Erve I, van Duijnhoven FJB, de Roos WK, Grosfeld S, Los M, Sommeijer DW, van Laarhoven HWM, Winkels RM, Kampman E.

Nutr Cancer. 2019 Jan 19:1-11. doi: 10.1080/01635581.2018.1559938. [Epub ahead of print]

PMID:
30661404
6.

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis.

van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Jan 11;11(1). pii: E80. doi: 10.3390/cancers11010080.

7.

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study.

Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M.

Biomed Opt Express. 2018 Aug 14;9(9):4196-4216. doi: 10.1364/BOE.9.004196. eCollection 2018 Sep 1.

8.

A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.

de Kruif JTCM, Visser M, van den Berg MMGA, Derks MJM, de Boer MR, van Laarhoven HWM, de Vries JHM, de Vries YC, Kampman E, Winkels RW, Westerman MJ.

BMC Cancer. 2019 Jan 5;19(1):7. doi: 10.1186/s12885-018-5207-7.

9.

Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid.

Henselmans I, Brugel SD, de Haes HCJM, Wolvetang KJA, de Vries LM, Pieterse AH, Baas-Thijssen MCM, de Vos FYF, van Laarhoven HWM, Smets EMA.

Patient Educ Couns. 2018 Dec 14. pii: S0738-3991(18)30412-9. doi: 10.1016/j.pec.2018.12.018. [Epub ahead of print]

PMID:
30591283
10.

The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer.

Jeene PM, van Laarhoven HWM, Hulshof MCCM.

Best Pract Res Clin Gastroenterol. 2018 Oct - Dec;36-37:53-59. doi: 10.1016/j.bpg.2018.11.011. Epub 2018 Nov 21. Review.

PMID:
30551857
11.

Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.

van den Ende T, Smyth E, Hulshof MCCM, van Laarhoven HWM.

Best Pract Res Clin Gastroenterol. 2018 Oct - Dec;36-37:45-52. doi: 10.1016/j.bpg.2018.11.005. Epub 2018 Nov 22. Review.

PMID:
30551856
12.

The dynamics in Health-Related Quality of Life of patients with Stable Coronary Artery Disease were revealed: a network analysis.

Oreel TH, Borsboom D, Epskamp S, Hartog ID, Netjes JE, Nieuwkerk PT, Henriques JPS, Scherer-Rath M, van Laarhoven HWM, Sprangers MAG.

J Clin Epidemiol. 2018 Dec 5. pii: S0895-4356(18)30688-7. doi: 10.1016/j.jclinepi.2018.11.022. [Epub ahead of print]

13.

An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study).

Kruizinga R, Scherer-Rath M, Schilderman JB, Hartog ID, Van Der Loos JP, Kotzé HP, Westermann AM, Klümpen HJ, Kortekaas F, Grootscholten C, Bossink F, Schrama J, Van De Vrande W, Schrama NA, Blokland W, De Vos FY, Kuin A, Meijer WG, Van Oijen MG, Sprangers MA, Van Laarhoven HW.

Palliat Med. 2018 Dec 5:269216318816005. doi: 10.1177/0269216318816005. [Epub ahead of print]

PMID:
30516096
14.

Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.

Mackay TM, van Erning FN, van der Geest LGM, de Groot JWB, Haj Mohammad N, Lemmens VE, van Laarhoven HW, Besselink MG, Wilmink JW; Dutch Pancreatic Cancer Group.

Eur J Cancer. 2019 Jan;106:99-105. doi: 10.1016/j.ejca.2018.10.008. Epub 2018 Nov 23.

PMID:
30476732
15.

Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by 1 H MRS.

Ter Voert EEGW, Heijmen L, van Asten JJA, Wright AJ, Nagtegaal ID, Punt CJA, de Wilt JHW, van Laarhoven HWM, Heerschap A.

NMR Biomed. 2019 Jan;32(1):e4035. doi: 10.1002/nbm.4035. Epub 2018 Nov 20.

PMID:
30457686
16.

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.

Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

17.

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients.

Klaassen R, Larue RTHM, Mearadji B, van der Woude SO, Stoker J, Lambin P, van Laarhoven HWM.

PLoS One. 2018 Nov 15;13(11):e0207362. doi: 10.1371/journal.pone.0207362. eCollection 2018.

18.

Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second Opinions.

Hillen MA, Woei-A-Jin FJSH, Smets EMA, van Maarschalkerweerd PEA, van Laarhoven HWM, Sommeijer DW.

JAMA Oncol. 2018 Oct 1;4(10):1425-1426. doi: 10.1001/jamaoncol.2018.3495. No abstract available.

PMID:
30422207
19.

Who should provide care for patients receiving palliative chemotherapy? A qualitative study among Dutch general practitioners and oncologists.

Wind J, Nugteren IC, van Laarhoven HWM, van Weert HCPM, Henselmans I.

Scand J Prim Health Care. 2018 Dec;36(4):437-445. doi: 10.1080/02813432.2018.1535264. Epub 2018 Oct 30.

PMID:
30375906
20.

Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.

van den Berg MMGA, Kok DE, Posthuma L, Kamps L, Kelfkens CS, Buist N, Geenen M, Haringhuizen A, Heijns JB, van Lieshout RHMA, Los M, Sommeijer DW, Timmer-Bonte JNH, de Kruif ATCM, van Laarhoven HWM, Kampman E, Winkels RM.

Breast Cancer Res Treat. 2018 Oct 23. doi: 10.1007/s10549-018-5014-5. [Epub ahead of print]

PMID:
30353244
21.

Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.

Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, Brosens LAA, Defize IL, van Dieren JM, Dijkstra H, van Hillegersberg R, Hulshof MC, van Laarhoven HWM, Lam MGEH, van Lier ALHMW, Muijs CT, Nagengast WB, Nederveen AJ, Noordzij W, Plukker JTM, van Rossum PSN, Ruurda JP, van Sandick JW, Weusten BLAM, Voncken FEM, Yakar D, Meijer GJ; PRIDE study group.

BMC Cancer. 2018 Oct 20;18(1):1006. doi: 10.1186/s12885-018-4892-6.

22.

Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) Trial.

Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, Swart KMA, van Laarhoven HW, van Schoor NM, de Groot LCPGM, Lemmens V, Stricker BH, Uitterlinden AG, van der Velde N.

Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):275-282. doi: 10.1158/1055-9965.EPI-17-1198. Epub 2018 Oct 19.

PMID:
30341095
23.

Relationship between physicians' death anxiety and medical communication and decision-making: A systematic review.

Draper EJ, Hillen MA, Moors M, Ket JCF, van Laarhoven HWM, Henselmans I.

Patient Educ Couns. 2019 Feb;102(2):266-274. doi: 10.1016/j.pec.2018.09.019. Epub 2018 Sep 25. Review.

PMID:
30293933
24.

Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis.

Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N, Sprangers MAG, van Oijen MGH, van Laarhoven HWM.

Eur J Cancer. 2018 Nov;103:214-226. doi: 10.1016/j.ejca.2018.07.132. Epub 2018 Sep 28. Review.

PMID:
30268922
25.

Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.

van Erning FN, Mackay TM, van der Geest LGM, Groot Koerkamp B, van Laarhoven HWM, Bonsing BA, Wilmink JW, van Santvoort HC, de Vos-Geelen J, van Eijck CHJ, Busch OR, Lemmens VE, Besselink MG; Dutch Pancreatic Cancer Group.

Acta Oncol. 2018 Dec;57(12):1655-1662. doi: 10.1080/0284186X.2018.1518593. Epub 2018 Sep 28.

PMID:
30264642
26.

Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.

Ter Veer E, van den Ende T, Creemers A, de Waal L, van Oijen MGH, van Laarhoven HWM.

Acta Oncol. 2018 Dec;57(12):1599-1604. doi: 10.1080/0284186X.2018.1503421. Epub 2018 Sep 28.

PMID:
30264641
27.

[Second opinion abroad; motives and experiences of patients with incurable cancer].

Hillen MA, Smets EMA, Onderwater A, van Laarhoven HWM, Sommeijer DW.

Ned Tijdschr Geneeskd. 2018 Aug 10;162. pii: D2513. Dutch.

PMID:
30211997
28.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

29.

Multidrug-resistant transporter expression does not always result in drug resistance.

Le Large TYS, El Hassouni B, Kazemier G, Piersma SR, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E.

Cancer Sci. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756. Epub 2018 Sep 8. No abstract available.

30.

Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial.

Ter Veer E, Prinsen H, Sprangers MAG, Zwinderman KAH, Bleijenberg G, van der Pouw Kraan TCTM, de Vries IJM, Wierenga EA, van Laarhoven HWM.

Cancer Invest. 2018;36(7):371-377. doi: 10.1080/07357907.2018.1499933. Epub 2018 Sep 6.

PMID:
30188739
31.

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2018 Sep 5;8(1):13281. doi: 10.1038/s41598-018-31548-6.

32.

Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer.

Larue RTHM, Klaassen R, Jochems A, Leijenaar RTH, Hulshof MCCM, van Berge Henegouwen MI, Schreurs WMJ, Sosef MN, van Elmpt W, van Laarhoven HWM, Lambin P.

Acta Oncol. 2018 Nov;57(11):1475-1481. doi: 10.1080/0284186X.2018.1486039. Epub 2018 Aug 1.

PMID:
30067421
33.

Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012.

Schroten-Loef C, Verhoeven RHA, de Hingh IHJT, van de Wouw AJ, van Laarhoven HWM, Lemmens VEPP.

Eur J Cancer. 2018 Sep;101:77-86. doi: 10.1016/j.ejca.2018.06.032. Epub 2018 Jul 20.

PMID:
30031970
34.

Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis.

Maracle CX, Jeucken KCM, Helder B, van Gulik TM, Steins A, van Laarhoven HWM, Tas SW.

Oncotarget. 2018 Jun 19;9(47):28445-28455. doi: 10.18632/oncotarget.25442. eCollection 2018 Jun 19.

35.

Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial.

Henselmans I, van Laarhoven HWM, de Haes HCJM, Tokat M, Engelhardt EG, van Maarschalkerweerd PEA, Kunneman M, Ottevanger PB, Dohmen SE, Creemers GJ, Sommeijer DW, de Vos FYFL, Smets EMA.

Oncologist. 2019 Feb;24(2):259-265. doi: 10.1634/theoncologist.2018-0090. Epub 2018 Jun 29.

PMID:
29959285
36.

The dynamics of HER2 status in esophageal adenocarcinoma.

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.

Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1.

37.

Group medical consultations (GMCs) and tablet-based online support group sessions in the follow-up of breast cancer: A multicenter randomized controlled trial.

Visser A, Prins JB, Jansen L, Radema SA, Schlooz MS, van Dalen T, van Laarhoven HWM.

Breast. 2018 Aug;40:181-188. doi: 10.1016/j.breast.2018.05.012. Epub 2018 Jun 12.

PMID:
29906741
38.

Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients.

Krikken E, Khlebnikov V, Zaiss M, Jibodh RA, van Diest PJ, Luijten PR, Klomp DWJ, van Laarhoven HWM, Wijnen JP.

Breast Cancer Res. 2018 Jun 14;20(1):51. doi: 10.1186/s13058-018-0982-2.

39.

Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients.

Klaassen R, Gurney-Champion OJ, Engelbrecht MRW, Stoker J, Wilmink JW, Besselink MG, Bel A, van Tienhoven G, van Laarhoven HWM, Nederveen AJ.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1052-1062. doi: 10.1016/j.ijrobp.2018.04.064. Epub 2018 May 4.

PMID:
29891208
40.

microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.

Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, Gisbertz SS, Medema JP, van Berge Henegouwen MI, Meijer SL, Bergman JJGHM, Milano F, Krishnadath KK.

Gastroenterology. 2018 Sep;155(3):784-798. doi: 10.1053/j.gastro.2018.06.030. Epub 2018 Jun 7.

PMID:
29885883
41.

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity.

Khurshed M, Aarnoudse N, Hulsbos R, Hira VVV, van Laarhoven HWM, Wilmink JW, Molenaar RJ, van Noorden CJF.

FASEB J. 2018 Jun 7:fj201800547R. doi: 10.1096/fj.201800547R. [Epub ahead of print]

42.

Patched-2 functions to limit Patched-1 deficient skin cancer growth.

Veenstra VL, Dingjan I, Waasdorp C, Damhofer H, van der Wal AC, van Laarhoven HW, Medema JP, Bijlsma MF.

Cell Oncol (Dordr). 2018 Aug;41(4):427-437. doi: 10.1007/s13402-018-0381-9. Epub 2018 Jun 4.

43.

Muscle Strength Is Associated With Muscle Mass in Patients With Esophageal Cancer Awaiting Surgery.

van Egmond MA, van der Schaaf M, Hagens ERC, van Laarhoven HWM, van Berge Henegouwen MI, Haverkort EB, Engelbert RHH, Gisbertz SS.

J Geriatr Phys Ther. 2018 Jun 1. doi: 10.1519/JPT.0000000000000200. [Epub ahead of print]

PMID:
29864049
44.

Accuracy of a single measurement site for self-monitoring of patients with breast cancer at risk for lymphedema.

Hidding JT, Beurskens CHG, De Vries MT, Nijhuis-van der Sanden MWG, van Laarhoven HWM, van der Wees PJ.

Physiother Theory Pract. 2018 May 14:1-6. doi: 10.1080/09593985.2018.1474404. [Epub ahead of print]

PMID:
29757069
45.

Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands.

Zijlstra M, van der Geest LGM, van Laarhoven HWM, Lemmens VEPP, van de Poll-Franse LV, Raijmakers NJH.

Acta Oncol. 2018 Sep;57(9):1185-1191. doi: 10.1080/0284186X.2018.1470330. Epub 2018 May 9.

PMID:
29741436
46.

Muslim physicians and palliative care: attitudes towards the use of palliative sedation.

Muishout G, van Laarhoven HWM, Wiegers G, Popp-Baier U.

Support Care Cancer. 2018 May 8. doi: 10.1007/s00520-018-4229-7. [Epub ahead of print]

47.

Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery.

Lagarde SM, Anderegg MCJ, Gisbertz SS, Meijer SL, Hulshof MCCM, Bergman JJGHM, van Laarhoven HWM, van Berge Henegouwen MI.

J Thorac Dis. 2018 Mar;10(3):1511-1521. doi: 10.21037/jtd.2018.02.81.

48.

Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study).

Brenkman HJF, Gertsen EC, Vegt E, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Sandick JW, van Grieken NCT, Heisterkamp J, van Etten B, Haveman JW, Pierie JP, Jonker F, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wessels FJ, Haj Mohammad N, van Stel HF, Frederix GWJ, Siersema PD, Ruurda JP; PLASTIC Study Group.

BMC Cancer. 2018 Apr 20;18(1):450. doi: 10.1186/s12885-018-4367-9.

49.

Are the effects of cognitive behavior therapy for severe fatigue in cancer survivors sustained up to 14 years after therapy?

Van Gessel LD, Abrahams HJG, Prinsen H, Bleijenberg G, Heins M, Twisk J, Van Laarhoven HWM, Verhagen SCAHHVM, Gielissen MFM, Knoop H.

J Cancer Surviv. 2018 Aug;12(4):519-527. doi: 10.1007/s11764-018-0690-z. Epub 2018 Apr 12.

PMID:
29651784
50.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators.

Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.

PMID:
29650363

Supplemental Content

Loading ...
Support Center